The bladder receives an extensive nerve supply that is predominantly cholin
ergic, but several putative transmitters are present, some of which are col
ocalized. Previous studies have shown increased levels of sensory nerves, r
educed inhibitory transmitters, and structural and functional changes in th
e excitatory input in unstable bladder conditions. The present study compar
ed the end-organ nerve supply to the bladder in spinal cord injury (SCI) wi
th uninjured controls. Acetylcholinesterase histochemistry and double-label
immunofluorescence were used to investigate neurotransmitter content, with
confocal laser scanning microscopy to assess colocalization. Organ bath st
udies provided functional correlates for the structural changes in the exci
tatory innervation. Control samples had dense innervation of the detrusor c
ontaining a diverse range of transmitters. Hyperreflexic SCI samples showed
patchy denervation, and areflexic SCI samples were diffusely denervated. V
asoactive intestinal polypeptide-, neuropeptide Y-, neuronal nitric oxide s
ynthase-, and galanin-immunoreactive nerve fibers were reduced from frequen
t or moderately frequent to infrequent or very infrequent in SCI. Calcitoni
n gene-related peptide-immunoreactive fibers were infrequent in controls an
d SCI samples. Patterns of colocalization were unchanged, but significantly
fewer fibers expressed more than one transmitter. The subepithelial plexus
was markedly reduced and several of the smaller coarse nerve trunks showed
no immunoreactivity to the transmitters assessed. There was no reduction i
n sensitivity to electrical field stimulation of intrinsic nerves in SCI, b
ut the maximum force generated by each milligram of bladder tissue and the
peak force as a proportion of the maximum carbachol contraction were signif
icantly reduced and the responses were protracted. There was no significant
functional atropine-resistant neuromuscular transmission in controls or SC
I. The reported findings have clinical implications in the management of ch
ronic SCI and development of new treatments.